Antimicrobial Peptide Cec4 Kills Carbapenem-Resistant Klebsiella at Low Doses and Destroys Its Biofilms

The researchers tested Cec4 against clinical CRKP isolates using standard antimicrobial susceptibility assays. Biofilm inhibition and eradication were quantified. Combination effects with traditional antibiotics were assessed. Membrane disruption was visualized using transmission electron microscopy, scanning electron microscopy, and confocal laser scanning microscopy. Membrane permeability was quantified by flow cytometry. DNA/RNA binding was demonstrated in vitro. In vivo efficacy was tested in a mouse skin wound infection model. Transcriptomic analysis was performed to characterize the antibacterial mechanism at the molecular level.

CRKP is classified as a critical-priority pathogen by the WHO because it resists nearly all available antibiotics. Infections carry mortality rates of 40-50% in some settings. Cec4's ability to kill CRKP at low concentrations, destroy biofilms (which make infections even harder to treat), and enhance existing antibiotics makes it a multi-pronged weapon against one of the most dangerous superbugs. The in vivo wound model validation moves it beyond lab curiosity toward clinical potential.

Cecropin-family peptides, originally discovered in insects, are among the most studied antimicrobial peptides. Cec4 adds to this legacy with specific activity against one of the WHO's most critical drug-resistant pathogens. The dual mechanism — membrane disruption plus nucleic acid binding — makes resistance development less likely than for single-target antibiotics. The biofilm eradication capability is particularly important since biofilms protect bacteria from both antibiotics and the immune system.

The in vivo testing was limited to a skin wound infection model, which may not represent deeper tissue or bloodstream CRKP infections. Specific MIC values against the clinical isolates were not detailed in the abstract beyond the 8 µg/mL biofilm concentration. Toxicity to mammalian cells and therapeutic index were not discussed. Long-term resistance development potential was not assessed. Pharmacokinetics and systemic administration feasibility were not explored.